

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Shanghai MicroPort MedBot (Group) Co., Ltd.**

**上海微创医疗机器人(集团)股份有限公司**

*(a joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 2252)**

**VOLUNTARY ANNOUNCEMENT  
HONGHU (鴻鵠®) ORTHOPEDIC SURGICAL ROBOT  
OBTAINED THE CE MARK IN EUROPE**

This announcement is made by Shanghai MicroPort MedBot (Group) Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis.

The board of directors of the Company (the “**Board**”) is pleased to announce that the SkyWalker™ Total Knee System (registered name in China of which is Honghu (鴻鵠®)) (the “**Honghu (鴻鵠®)**”), which is independently developed by the Group, has successfully obtained the CE Mark in Europe, becoming the first joint replacement surgical robot in China with the CE Mark in Europe. Also, Honghu (鴻鵠®) is currently the first and only domestic surgical robot that has obtained the approval from the National Medical Products Administration (the “**NMPA**”), the clearance from the U.S. Food and Drug Administration (the “**FDA**”) and the CE Mark.

**ABOUT HONGHU (鴻鵠®)**

Honghu (鴻鵠®) enjoys technical advantages such as precise operation, efficient synergy, safety protection and strong compatibility. Before surgery, its planning system can assist surgeons to formulate personalized prosthesis implantation plans based on patients’ preoperative CT scan data and prosthesis model data. During surgery, the precise positioning from surgical planning and the utilisation of registration technology in combination with the self-developed highly dexterous and lightweight robotic arm(s) allow for an osteotomy to be quickly completed, thus helping to improve the accuracy and efficiency of the operation. Honghu (鴻鵠®) avoids the need for positioning of the medullary cavity in traditional surgery. As there is no intramedullary rod implantation during the surgery, Honghu (鴻鵠®) reduces surgical damage and blood loss, improves the postoperative lower limb alignment, reduces surgical complications, and helps patients achieve faster recovery after surgery.

## **IMPACT ON THE COMPANY**

Obtaining the CE Mark for Honghu (鴻鵠<sup>®</sup>) embarks the first step for the Group to enter the European Union market. It is also another significant achievement made by Honghu (鴻鵠<sup>®</sup>) after obtaining the approval from the NMPA in April and the clearance from the FDA in July this year. Honghu (鴻鵠<sup>®</sup>) has been certified in China, the United States and the European Union within one year, demonstrating the strong technical strength and product advantages of domestic surgical robots, marking the preliminary completion of the Group's business layout of gaining permits in key regions all over the world. This will also help the Group to accelerate its strategy for globalisation, benefit more patients around the world, and realise the belief of “make surgery easier, safer and less invasive”.

**Shareholders of the Company and potential investors are advised to exercise caution when dealing in shares of the Company.**

By order of the Board  
**Shanghai MicroPort MedBot (Group) Co., Ltd.**  
*Chairman*  
**Mr. Sun Hongbin**

Shanghai, China, 5 December 2022

*As at the date of this announcement, the executive director of the Company is Dr. He Chao, the non-executive directors of the Company are Mr. Sun Hongbin, Mr. Sun Xin and Mr. Chen Chen, and the independent non-executive directors of the Company are Dr. Li Minghua, Mr. Yao Haisong and Mr. Mui Wing Hong.*